Impacts of the Zero-Markup Drug Policy on Hospitalization Expenses of Patients with Stroke in Western China: An Interrupted Time Series Analysis

References

• Yip WC, Hsiao W, Meng Q, Chen W, Sun X. Realignment of incentives for health-care providers in China. Lancet. 2010;375(9720):1120–1130. doi:10.1016/s0140-6736(10)60063-3
   PubMed Web of Science ®Google Scholar
• Wagstaff A, Yip W, Lindelow M, Hsiao WC. China’s health system and its reform: a review of recent studies. Health Econ. 2009;18(Suppl 2):S7–S23. doi:10.1002/hec.1518
   PubMedGoogle Scholar
• Shi L, Yang HY, Cheng G, Meng Q. Time trends and determinants of pharmaceutical expenditure in China (1990–2009). Pharmacoeconomics. 2014;32(3):257–264. doi:10.1007/s40273-013-0072-3
   PubMed Web of Science ®Google Scholar
• Jiang Q, Yu BN, Ying G, et al. Outpatient prescription practices in rural township health centers in Sichuan Province, China. BMC Health Serv Res. 2012;12:324. doi:10.1186/1472-6963-12-324
   PubMed Web of Science ®Google Scholar
• Currie J, Lin W, Meng J. Addressing antibiotic abuse in China: an Experimental Audit Study. J Dev Econ. 2014;110:39–51. doi:10.1016/j.jdeveco.2014.05.006
   PubMed Web of Science ®Google Scholar
• Li Y, Xu J, Wang F, et al. Overprescribing in China, driven by financial incentives, results in very high use of antibiotics, injections, and corticosteroids. Health Aff. 2012;31(5):1075–1082. doi:10.1377/hlthaff.2010.0965
   PubMed Web of Science ®Google Scholar
• Liu M, Jia M, Lin Q, Zhu J, Wang D. Effects of Chinese medical pricing reform on the structure of hospital revenue and healthcare expenditure in county hospital: an interrupted time series analysis. BMC Health Serv Res. 2021;21(1):385. doi:10.1186/s12913-021-06388-2
   PubMed Web of Science ®Google Scholar
• Gao L, Shi L, Meng Q, Kong X, Guo M, Lu F. Effect of healthcare system reforms on public hospitals’ revenue structures: evidence from Beijing, China. Soc Sci Med. 2021;283:114210. doi:10.1016/j.socscimed.2021.114210
   PubMed Web of Science ®Google Scholar
• Shi X, Zhu D, Man X, et al. The biggest reform to China’s health system”: did the zero-markup drug policy achieve its goal at traditional Chinese medicines county hospitals? Health Policy Plan. 2019;34(7):483–491. doi:10.1093/heapol/czz053
   PubMed Web of Science ®Google Scholar
• Collaborators. GS. Global, regional, and national burden of stroke and its risk factors, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Neurol. 2021;20(10):795–820. doi:10.1016/s1474-4422(21)00252-0
   PubMed Web of Science ®Google Scholar
• Zhou M, Wang H, Zeng X, et al. Mortality, morbidity, and risk factors in China and its provinces, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2019;394(10204):1145–1158. doi:10.1016/s0140-6736(19)30427-1
   PubMed Web of Science ®Google Scholar
• Ergul A, Hafez S, Fouda A, Fagan SC. Impact of comorbidities on acute injury and recovery in preclinical stroke research: focus on hypertension and diabetes. Transl Stroke Res. 2016;7(4):248–260. doi:10.1007/s12975-016-0464-8
   PubMed Web of Science ®Google Scholar
• Arboix A, Massons J, García-Eroles L, et al. Nineteen-year trends in risk factors, clinical characteristics and prognosis in lacunar infarcts. Neuroepidemiology. 2010;35(3):231–236. doi:10.1159/000319460
   PubMed Web of Science ®Google Scholar
• Arboix A, Oliveres M, Massons J, Pujades R, Garcia-Eroles L. Early differentiation of cardioembolic from atherothrombotic cerebral infarction: a multivariate analysis. Eur J Neurol. 1999;6(6):677–683. doi:10.1046/j.1468-1331.1999.660677.x
   PubMed Web of Science ®Google Scholar
• Zhu D, Shi X, Nicholas S, et al. Medical service utilization and direct medical cost of stroke in Urban China. Int J Health Policy Manag. 2022;11(3):277–286. doi:10.34172/ijhpm.2020.111
   PubMed Web of Science ®Google Scholar
• Liu L, Xu Y, Jiang Y, et al. Impact of Beijing healthcare reform on the curative care expenditure of outpatients with noncommunicable diseases based on SHA2011 and interrupted time series analysis. BMC Health Serv Res. 2021;21(1):1045. doi:10.1186/s12913-021-07059-y
   PubMed Web of Science ®Google Scholar
• Du J, Xie J, Qian Y, et al. Impact of China’s zero mark-up drug policy on drug cost of NCDs’ outpatients: an interrupted time series analysis. BMC Health Serv Res. 2021;21(1):404. doi:10.1186/s12913-021-06414-3
   PubMed Web of Science ®Google Scholar
• Linden A, Adams JL. Applying a propensity score-based weighting model to interrupted time series data: improving causal inference in programme evaluation. J Eval Clin Pract. 2011;17(6):1231–1238. doi:10.1111/j.1365-2753.2010.01504.x
   PubMed Web of Science ®Google Scholar
• Li L, Cuerden MS, Liu B, Shariff S, Jain AK, Mazumdar M. Three statistical approaches for assessment of intervention effects: a primer for practitioners. Risk Manag Healthc Policy. 2021;14:757–770. doi:10.2147/rmhp.S275831
   PubMed Web of Science ®Google Scholar
• Penfold RB, Zhang F. Use of interrupted time series analysis in evaluating health care quality improvements. Acad Pediatr. 2013;13(6 Suppl):S38–S44. doi:10.1016/j.acap.2013.08.002
   PubMed Web of Science ®Google Scholar
• Nistal-Nuño B. Segmented regression analysis of interrupted time series data to assess outcomes of a South American road traffic alcohol policy change. Public Health. 2017;150:51–59. doi:10.1016/j.puhe.2017.04.025
   PubMed Web of Science ®Google Scholar
• Turner SL, Forbes AB, Karahalios A, Taljaard M, McKenzie JE. Evaluation of statistical methods used in the analysis of interrupted time series studies: a simulation study. BMC Med Res Methodol. 2021;21(1):181. doi:10.1186/s12874-021-01364-0
   PubMed Web of Science ®Google Scholar
• Yu SC, Wang QQ, Long XJ, et al. 变量自然对数转换的多重线性回归 [Multiple linear regression models with natural logarithmic transformations of variables]. Zhonghua Yu Fang Yi Xue Za Zhi. 2020;54(4):451–456. Chinese. doi:10.3760/cma.j.cn112150-20191030-00824
   PubMedGoogle Scholar
• Chen Y. Spatial autocorrelation approaches to testing residuals from least squares regression. PLoS One. 2016;11(1):e0146865. doi:10.1371/journal.pone.0146865
   PubMed Web of Science ®Google Scholar
• Chang AY, Skirbekk VF, Tyrovolas S, Kassebaum NJ, Dieleman JL. Measuring population ageing: an analysis of the Global Burden of Disease Study 2017. Lancet Public Health. 2019;4(3):e159–e167. doi:10.1016/s2468-2667(19)30019-2
   PubMed Web of Science ®Google Scholar
• Alpérovitch A, Kurth T, Bertrand M, et al. Primary prevention with lipid lowering drugs and long term risk of vascular events in older people: population based cohort study. BMJ. 2015;350:h2335. doi:10.1136/bmj.h2335
   PubMed Web of Science ®Google Scholar
• Schulz UG. Drug treatments in the secondary prevention of ischaemic stroke. Maturitas. 2013;76(3):267–271. doi:10.1016/j.maturitas.2013.05.009
   PubMed Web of Science ®Google Scholar
• Hackam DG, Spence JD. Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke. 2007;38(6):1881–1885. doi:10.1161/strokeaha.106.475525
   PubMed Web of Science ®Google Scholar
• Ricci S, Celani MG, Cantisani TA, Righetti E. Piracetam for acute ischaemic stroke. Cochrane Database Syst Rev. 2012;2012(9):Cd000419. doi:10.1002/14651858.CD000419.pub3
   PubMedGoogle Scholar
• Gu HQ, Xie XW, Jing J, et al. Shuxuetong for Prevention of recurrence in Acute Cerebrovascular events with Embolism (SPACE) trial: rationale and design. Stroke Vasc Neurol. 2020;5(3):311–314. doi:10.1136/svn-2019-000293
   PubMedGoogle Scholar
• Blumenthal D, Hsiao W. Privatization and its discontents--the evolving Chinese health care system. N Engl J Med. 2005;353(11):1165–1170. doi:10.1056/NEJMhpr051133
   PubMed Web of Science ®Google Scholar
• Shang L, Lin Y, Fang W, et al. How national health insurance coverage policy affected the use of trastuzumab and rituximab in China: a Bicentric Retrospective Study. Risk Manag Healthc Policy. 2023;16:1739–1753. doi:10.2147/rmhp.S420899
   PubMed Web of Science ®Google Scholar
• Zhu Z, Wang J, Sun Y, Zhang J, Han P, Yang L. The impact of zero markup drug policy on patients’ healthcare utilization and expense: an interrupted time series study. Front Med. 2022;9:928690. doi:10.3389/fmed.2022.928690
   Web of Science ®Google Scholar
• Zeng J, Chen X, Fu H, Lu M, Jian W. Short-term and long-term unintended impacts of a pilot reform on Beijing’s zero markup drug policy: a propensity score-matched study. BMC Health Serv Res. 2019;19(1):916. doi:10.1186/s12913-019-4764-z
   PubMed Web of Science ®Google Scholar
• Liu X, Xu J, Yuan B, Ma X, Fang H, Meng Q. Containing medical expenditure: lessons from reform of Beijing public hospitals. BMJ. 2019;365:l2369. doi:10.1136/bmj.l2369
   PubMedGoogle Scholar
• Liu S, Xu H, Cui X, Qian Y. How the implementation of drug zero markup policy will affect health care expenditure in hospitals: observation and prediction based on Zhejiang Model. Value Health. 2014;17(7):A790. doi:10.1016/j.jval.2014.08.432
   PubMed Web of Science ®Google Scholar
• Tang X, Zhang X, Chen Y, Yan J, Qian M, Ying X. Variations in the impact of the new case-based payment reform on medical costs, length of stay, and quality across different hospitals in China: an interrupted time series analysis. BMC Health Serv Res. 2023;23(1):568. doi:10.1186/s12913-023-09553-x
   PubMed Web of Science ®Google Scholar
• Yi H, Miller G, Zhang L, Li S, Rozelle S. Intended and unintended consequences of China’s zero markup drug policy. Health Aff. 2015;34(8):1391–1398. doi:10.1377/hlthaff.2014.1114
   PubMed Web of Science ®Google Scholar